Skip to main content

Table 1 Demographic characteristics of the included studies

From: Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials

Author Study design Target Population Treatment duration n Study groups Age, years Female, n (%) BMI, kg/m2 Total cholesterol, mg/dL LDL-C, mg/dL HDL-C, mg/dL Triglycerides, mg/dL Lp(a), mg/dL Lp(a) change, mg/dL
Athyros et al. (2002) [52] Randomized, open-label trial Type 2 diabetes and combined hyperlipidemia 24 weeks 40
40
40
Atorvastatin 20 mg/day
Fenofibrate 200 mg/day
Atorvastatin 20 mg/day + fenofibrate 200 mg/day
57 (44–67)a
58 (48–69)a
58 (50–68)a
17 (42.5)
18 (45.0)
17 (42.5)
ND
ND
ND
252 ± 17
253 ± 17
255 ± 19
161 ± 15
163 ± 15
163 ± 16
34.6 ± 3.2
34.8 ± 3.4
35.1 ± 3.5
278 ± 24
281 ± 24
278 ± 23
18.4 ± 3.7
20.1 ± 5.2
19.2 ± 4.1
2.0
–4.0
1.0
Bredie et al. (1996) [55] Randomized, double-blind, placebo-controlled trial Familial combined hyperlipidemia 12 weeks 41
40
Simvastatin 20 mg/day Gemfibrozil 1200 mg/day 50.4 ± 10.8
53.4 ± 9.4
9 (21.9)
14 (35.0)
26.6 ± 2.7
27.2 ± 3.0
282.2 ± 37.1
290.0 ± 37.8
149.6 ± 37.8
157.7 ± 38.2
32.4 ± 7.3
35.1 ± 7.7
283.4 ± 106.2
285.2 ± 108.0
19.6b
18.0b
6.5
2.7
Hansen et al. (1994) [60] Randomized, cross-over trial Familial defective apolipoprotein
B-100
8 weeks 17
13
Pravastatin 40 mg/day
Gemfibrozil 1200 mg/day
45.8 ± 17.1
40.8 ± 12.3
12 (70.5)
7 (53.8)
ND
ND
320.9 ± 58.0
320.9 ± 46.4
247.4 ± 54.1
235.8 ± 42.5
46.4 ± 7.7
50.2 ± 19.3
115.1 (79.7–168.2)a
141.7 (106.2–230.2)a
10.5 (3.5–16.7)a
8.3 (3.4–12.9)a
0.9
1.1
Perez-Jimenez et al. (1995)
[61]
Randomized, cross-over trial Patients with heart transplant 8 weeks 18
18
Lovastatin 10 mg/day
Bezafibrate 400 mg/day
54 ± 2 2 (11.1) ND 302 ± 7
307 ± 5
213 ± 5
212 ± 5
54 ± 3
51 ± 4
170 ± 15
201 ± 17
34 ± 9
37 ± 9
5.0
–13.0
Melenovsky et al. (2002)
[51]
Randomized, open-label, cross-over trial Combined hyperlipidemia 10 weeks 15
14
Fenofibrate 200 mg/day
Atorvastatin 10 mg/day
48.0 ± 6.9
46.4 ± 8.9
ND
ND
27.7 ± 2.3
27.9 ± 3.2
300.0 ± 56.4
283.0 ± 35.9
174.7 ± 46.4
165.8 ± 23.2
49.4 ± 8.8
47.9 ± 15.8
492.4 ± 440.2
465.0 ± 372.8
24 ± 29
17 ± 23
2.8
1.8
Ohrvall et al. (1995) [54] Randomized, double-blind, cross-over trial Diabetes and hyperlipo-proteinemia 4 months 25
24
Gemfibrozil 1200 mg/day
Simvastatin 10 mg/day
63.7 (48–78)a 9 (31.0) ND 232.0 ± 40.2 152.7 ± 43.3 36.7 ± 6.9 116.0 ± 52.5 37.77 ± 54.75 –7.0
–2.4
Ramires et al. (1995) [62] Randomized clinical trial Hyperlipidemia and hyperlipo-proteinemia 12 weeks 14
13
Gemfibrozil 1200 mg/day
Lovastatin 40-80 mg/day
54 ± 7
55 ± 9
5 (55.5)
3 (30.0)
ND
ND
298.9 ± 12.3
299.3 ± 11.2
209.9 ± 20.8
208.0 ± 11.9
31.7 ± 7.3
34.4 ± 6.1
295.8 ± 23.0
281.6 ± 20.3
29.8 ± 5.7
27.8 ± 4.1
–7.5
1.4
Bairaktari et al. (1999) [50] Open-label trial Mixed hyperlipidemia 16 weeks 45
46
Atorvastatin 10 mg/day
Fenofibrate 200 mg/day
49 ± 8
46 ± 10
16 (35.5)
15 (32.6)
26.8 ± 4
27.4 ± 3
278 ± 34
282 ± 37
198 ± 29
199 ± 36
40 ± 11
36 ± 16
271 ± 59
269 ± 60
14 ± 12
11.8 ± 10.5
1.2
–1.8
Davidson et al. (2009) [53] Randomized, double-blind trial Dyslipidemia 12 weeks 74
73
73
Atorvastatin 40 mg/day
Fenofibrate 145 mg/day
Atorvastatin 40 mg/day + fenofibrate 100 mg/day
56.3 ± 9.8
56.4 ± 10.5
54.9 ± 10.7
39 (52.7)
33 (45.2)
33 (45.2)
ND
ND
ND
254.4 ± 44.2
251.9 ± 47.5
252.0 ± 40.1
165.0 ± 37.7
166.6 ± 46.7
156.2 ± 33.6
42.7b
41.2b
43.3b
265.1b
227.3b
270.2b
69.0 ± 67.5
66.0 ± 65.3
76.8 ± 74.5
9.3
5.1
6.9
Greten et al. (1994) [64] Randomized, double-blind trial Primary hypercholesterolemia 12 weeks 64
67
Fluvastatin 40 mg/day
Bezafibrate 400 mg/day
53.0 (18–75)a
51.8 (22–70)a
37 (57.8)
37 (55.2)
24.6 (18.6–31.2)a
24.7 (16.9–31.6)a
352.7 ± 89.4
340.3 ± 76.7
268.9 ± 88.5
257.4 ± 75.6
55.2 ± 12.2
55.2 ± 12.6
143.2 ± 48.0
138.0 ± 59.4
12.0 ± 16.5
14.0 ± 30.0
1.0
0.4
Kehely et al. (1995) [56] Randomized, double-blind trial Mixed hyperlipidemia 3 months 53
27
26
Placebo
Simvastatin 20 mg/day
Bezafibrate 400 mg/day
ND
52 ± 9
49 ± 10
ND
11 (40.7)
4 (15.3)
ND
ND
ND
298.5 ± 51.8 189.0 ± 54.9 42.5 ± 8.1 286.9 ± 122.2 19.8 ± 2.8 5.7
–2.5
May et al. (2008) [57] Randomized, double-blind, placebo-controlled trial Diabetes and mixed dyslipidemia 12 weeks 100
100
100
Fenofibrate 160 mg/day
Simvastatin 20 mg/day
Fenofibrate 160 mg/day +
Simvastatin 20 mg/day
61.6 ± 11.5 135 (45.0) ND ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
4.0 (2.0–6.0)a
4.0 (2.0–6.0)a
5.0 (3.0–9.0)a
1.0
1.0
0.0
Ramires et al. (1997) [63] Randomized clinical trial Hypercholesterolemia and hyperlipoproteinemia 12 weeks 14
13
Gemfibrozil 1200 mg/day
Lovastatin 40-80 mg/day
54 ± 7
55 ± 9
5 (36.0)
6 (59.0)
ND
ND
306 ± 13
307 ± 11
215 ± 21
213 ± 12
33 ± 7
35 ± 6
294 ± 23
280 ± 20
51 ± 10
48 ± 7
–13.0
–2.0
Saougos et al. (2007) [65] Clinical trial Hyperlipidemia 2 months 50
50
Rosuvastatin 10 mg/day
Fenofibrate 200 mg/day
54.6 ± 14.6
55.9 ± 11
31 (62.0)
30 (60.0)
25.8 ± 4.2
34.3 ± 7
297.7 ± 50.2
235.8 ± 34.8
208.8 ± 42.5
146.9 ± 34.8
58.0 ± 11.6
50.2 ± 11.6
141.7 ± 53.1
239.1 ± 53.1
4.0 (2.0–7.4)a
3.8 (2.0–7.9)a
0.0
0.1
Vigna et al. (1999) [58] Randomized, double-blind trial Men with mixed hyperlipidemia 2 months 15
15
Gemfibrozil 1200 mg/day
Simvastatin 20 mg/day
53.6 ± 11.7
50.9 ± 9.9
0 (0.0)
0 (0.0)
26.7 ± 1.9
25.0 ± 2.5
280.2 ± 30.1
281.2 ± 38.8
208.5 ± 30.1
206.7 ± 37.8
46.1 ± 9.9
44.4 ± 8.2
46.1 ± 9.9
44.4 ± 8.2
25.7 ± 22.6
9.2 ± 11.8
–4.3
2.1
de Lorgeril et al. (1999) [59] Randomized, double-blind trial Dyslipidemic coronary patients 12 weeks 32
32
Fenofibrate 200 mg/day
Simvastatin 20 mg/day
ND ND ND 278.4 ± 27.0
278.4 ± 27.0
193.3 ± 27.0
197.2 ± 23.2
46.4 ± 11.6
46.4 ± 7.7
186.0 ± 79.7
168.2 ± 88.5
34 ± 62
32 ± 39
–6.0
–2.0
  1. Values are expressed as mean ± SD
  2. aMedian (interquartile range)
  3. bMean only
  4. BMI body mass index, ND no data